FDA Gives Accelerated Approval for Risky Alzheimer’s Pill
The Alzheimer's medication Leqembi received fast-tracked approval even though it causes life-threatening adverse events and is targeting a component of the disease that many believe is misunderstood.
The U.S. Food and Drug Administration (FDA) granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi)
The drug, a monoclonal antibody, binds to amyloid beta in the brain
The most common reactions included amyloid-related imaging abnormalities, or ARIA, which involves swelling and bleeding in the brain that can be l…
Keep reading with a 7-day free trial
Subscribe to Dr. Mercola's Censored Library (Private Membership) to keep reading this post and get 7 days of free access to the full post archives.